Literature DB >> 27721717

Lymph Node Surgery - Stepwise Retirement for the Breast Surgeon?

Julia Landin1, Walter P Weber1.   

Abstract

Axillary lymph node dissection (ALND) has been standard of care for all patients with breast cancer until the 1990s. The stepwise retreat of breast surgeons from the axilla began after the introduction of the sentinel lymph node procedure. The evidence based clinical trend toward the omission of ALND has advanced to include patients with affected nodes, and several ongoing randomized controlled trials are evaluating the remaining indications for ALND. Conflicting with this trend toward less axillary surgery, indication and extent of regional nodal irradiation are currently broadened, equally supported by evidence from randomized trials. The present review summarizes this conflicting evidence, presents ongoing trials, and discusses the current and future optimal regional management of patients with affected nodes.

Entities:  

Keywords:  Breast cancer; Lymph node dissection; Sentinel lymph node

Year:  2016        PMID: 27721717      PMCID: PMC5040881          DOI: 10.1159/000448697

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN: 1661-3791            Impact factor:   2.860


  35 in total

1.  Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation.

Authors:  Bernard Fisher; Jong-Hyeon Jeong; Stewart Anderson; John Bryant; Edwin R Fisher; Norman Wolmark
Journal:  N Engl J Med       Date:  2002-08-22       Impact factor: 91.245

2.  Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.

Authors:  A S Coates; E P Winer; A Goldhirsch; R D Gelber; M Gnant; M Piccart-Gebhart; B Thürlimann; H-J Senn
Journal:  Ann Oncol       Date:  2015-05-04       Impact factor: 32.976

3.  Preoperative axillary ultrasound and fine-needle aspiration biopsy in the diagnosis of axillary metastases in patients with breast cancer: predictors of accuracy and future implications.

Authors:  Jonathan Cools-Lartigue; Alison Sinclair; Nora Trabulsi; Ari Meguerditchian; Benoit Mesurolle; Rebecca Fuhrer; Sarkis Meterissian
Journal:  Ann Surg Oncol       Date:  2012-09-13       Impact factor: 5.344

4.  A randomized trial comparing axillary dissection to no axillary dissection in older patients with T1N0 breast cancer: results after 5 years of follow-up.

Authors:  Gabriele Martelli; Patrizia Boracchi; Michaela De Palo; Silvana Pilotti; Saro Oriana; Roberto Zucali; Maria Grazia Daidone; Giuseppe De Palo
Journal:  Ann Surg       Date:  2005-07       Impact factor: 12.969

5.  Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer.

Authors:  Philip M Poortmans; Sandra Collette; Carine Kirkove; Erik Van Limbergen; Volker Budach; Henk Struikmans; Laurence Collette; Alain Fourquet; Philippe Maingon; Mariacarla Valli; Karin De Winter; Simone Marnitz; Isabelle Barillot; Luciano Scandolaro; Ernest Vonk; Carla Rodenhuis; Hugo Marsiglia; Nicola Weidner; Geertjan van Tienhoven; Christoph Glanzmann; Abraham Kuten; Rodrigo Arriagada; Harry Bartelink; Walter Van den Bogaert
Journal:  N Engl J Med       Date:  2015-07-23       Impact factor: 91.245

6.  Axillary lymph node dissection versus no dissection in patients with T1N0 breast cancer: a randomized clinical trial (INT09/98).

Authors:  Roberto Agresti; Gabriele Martelli; Marco Sandri; Elda Tagliabue; Maria Luisa Carcangiu; Ilaria Maugeri; Cristina Pellitteri; Cristina Ferraris; Giuseppe Capri; Angela Moliterni; Giulia Bianchi; Gabriella Mariani; Giovanna Trecate; Laura Lozza; Martin Langer; Mario Rampa; Massimiliano Gennaro; Marco Greco; Sylvie Menard; Marco A Pierotti
Journal:  Cancer       Date:  2013-12-05       Impact factor: 6.860

7.  Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial.

Authors:  Viviana Galimberti; Bernard F Cole; Stefano Zurrida; Giuseppe Viale; Alberto Luini; Paolo Veronesi; Paola Baratella; Camelia Chifu; Manuela Sargenti; Mattia Intra; Oreste Gentilini; Mauro G Mastropasqua; Giovanni Mazzarol; Samuele Massarut; Jean-Rémi Garbay; Janez Zgajnar; Hanne Galatius; Angelo Recalcati; David Littlejohn; Monika Bamert; Marco Colleoni; Karen N Price; Meredith M Regan; Aron Goldhirsch; Alan S Coates; Richard D Gelber; Umberto Veronesi
Journal:  Lancet Oncol       Date:  2013-03-11       Impact factor: 41.316

8.  DBCG-IMN: A Population-Based Cohort Study on the Effect of Internal Mammary Node Irradiation in Early Node-Positive Breast Cancer.

Authors:  Lise Bech Jellesmark Thorsen; Birgitte Vrou Offersen; Hella Danø; Martin Berg; Ingelise Jensen; Anders Navrsted Pedersen; Sune Jürg Zimmermann; Hans-Jürgen Brodersen; Marie Overgaard; Jens Overgaard
Journal:  J Clin Oncol       Date:  2015-11-23       Impact factor: 44.544

9.  Ultrasound-guided fine-needle aspiration of suspicious nodes in breast cancer patients; selecting patients with extensive nodal involvement.

Authors:  B J van Wely; J H W de Wilt; P J C Schout; B Kooistra; C A P Wauters; D Venderinck; L J A Strobbe
Journal:  Breast Cancer Res Treat       Date:  2013-06-30       Impact factor: 4.872

Review 10.  It is not always necessary to do axillary dissection for T1 and T2 breast cancer--point.

Authors:  Monica Morrow
Journal:  Cancer Res       Date:  2013-12-15       Impact factor: 12.701

View more
  1 in total

1.  Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial.

Authors:  Guido Henke; Michael Knauer; Karin Ribi; Stefanie Hayoz; Marie-Aline Gérard; Thomas Ruhstaller; Daniel R Zwahlen; Simone Muenst; Markus Ackerknecht; Hanne Hawle; Florian Fitzal; Michael Gnant; Zoltan Mátrai; Bettina Ballardini; Andreas Gyr; Christian Kurzeder; Walter P Weber
Journal:  Trials       Date:  2018-12-04       Impact factor: 2.279

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.